- 35-day median time from prescription to first infusion, significantly faster than traditional memory clinics.
- 7% ARIA-E rate in telehealth cohort, lower than pivotal clinical trials (12.6% for lecanemab, 24.0% for donanemab).
- 100% completion rate for all 45 label-required safety MRIs in the study.
Experts agree that telehealth models for Alzheimer's drug delivery show promising early results, but caution that long-term safety, reimbursement challenges, and operational guardrails require further validation.
Dismantling the Specialist Desert: Telehealth Unlocks Alzheimer's Drugs
BOSTON – November 16, 2026 -- The arrival of amyloid-targeted therapies has heralded a new era in Alzheimer's disease treatment, yet a stark geographic divide threatens to lock these breakthroughs behind multi-month waits at distant academic medical centers. For thousands of patients, the barrier to slowing cognitive decline is not a lack of local infusion chairs or MRI machines, but the scarcity of specialized cognitive neurologists required to prescribe and monitor these complex biologics.
Today, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, virtual specialty practice Synapticure presented early retrospective data that could fundamentally rewrite the playbook for specialty drug delivery. The findings suggest that amyloid-targeted therapies for early symptomatic Alzheimer's disease can be safely evaluated, prescribed, and monitored through a fully remote telehealth model.
The Virtual Biologic Playbook
The retrospective study reviewed 28 patients across 10 states who received either lecanemab (Leqembi) or donanemab (Kisunla) through a proprietary digital platform between July 2025 and October 2026. Rather than forcing patients to travel to urban hubs, fellowship-trained cognitive neurologists conducted all specialist care, including initial cognitive testing, via video.
Dedicated remote care coordinators managed the logistical heavy lifting: vetting local imaging and infusion sites, securing prior authorizations, and maintaining constant communication with families. The results demonstrated a median time of just 35 days from prescription to first infusion—a stark contrast to the months-long waitlists typical at traditional memory clinics.
"Most of what ATT requires, the imaging and the infusion chairs, already exists in communities across the country. What's scarce is the specialist oversight," said Oleg Yerstein, MD, the study's corresponding author. "This study suggests that specialist care can be delivered remotely, with a remote care coordinator helping the patient navigate local services like infusions and MRIs."
The cohort received 183 infusions, representing approximately 119 patient-months of exposure. Notably, three patients successfully completed a full 12-to-18-month donanemab course, confirmed by a negative follow-up amyloid PET scan indicating treatment completion per FDA guidelines.
Remote ARIA Vigilance: A High-Stakes Gamble?
The most significant hurdle in decentralized Alzheimer's care is the management of amyloid-related imaging abnormalities (ARIA), which include brain edema (ARIA-E) and microhemorrhages (ARIA-H). These complications require stringent, label-mandated MRI monitoring to ensure patient safety.
The presented data showed a 100% completion rate for all 45 label-required safety MRIs, which were completed and reviewed by a neurologist a median of nine days before the corresponding infusion. ARIA-E occurred in two patients (7%), with one patient discontinuing treatment. Crucially, there were no macrohemorrhages and no deaths in the cohort.
This 7% ARIA-E rate compares favorably to pivotal clinical trials. In the Clarity AD Phase 3 trial for lecanemab, the ARIA-E incidence was 12.6%, while donanemab's TRAILBLAZER-ALZ 2 trial saw a 24.0% rate. Early real-world data from the ALZ-NET registry, which tracks patients receiving FDA-approved Alzheimer's treatments, indicated a 10.3% ARIA-E rate for lecanemab among its first 2,000 enrolled patients. The smaller telehealth cohort aligns well with, and even slightly improves upon, these broader real-world observations.
Despite these promising figures, independent cognitive neurologists urge cautious optimism. While validated cognitive assessments can be administered via video, some experts note that the absence of an in-person physical examination removes a critical layer of clinical observation. Subtle clinical cues, nuanced gait abnormalities, or minor focal neurological deficits that might signal early symptomatic ARIA could potentially be missed on a two-dimensional screen. Remote models heavily rely on accurate and timely symptom reporting by patients and their caregivers, introducing a variable that requires rigorous patient education and continuous remote check-ins.
"We set out to build a model in which patients can safely receive a complex treatment from specialists entirely through telehealth, one where living near the specialist is not a requirement," said Jeremy J. Pruzin, MD, the study's first author. "In our initial experience, patients in 10 states were treated this way. Every required safety MRI was completed before infusion, and both ARIA cases were caught by the monitoring the program was built around."
Navigating Local Infrastructure and Emergency Readiness
Delegating high-risk biologic drug monitoring to distributed imaging centers requires meticulous operational guardrails. A successful remote model hinges entirely on the competency of local infrastructure and adherence to best practices, such as those outlined by the National Infusion Center Association (NICA).
To mitigate risks, virtual models must ensure community imaging centers meet stringent accreditation standards for brain MRI acquisition. This includes verifying that local machines are capable of generating the high-resolution images and specific sequences, like FLAIR and T2*, necessary for detecting subtle ARIA. Furthermore, the interpreting community radiologists must be experienced in neuroimaging and specifically trained to recognize the unique radiological signatures of amyloid-targeting therapies, which can differ from standard stroke or tumor presentations.
Emergency readiness is equally critical. In rare instances, ARIA can progress rapidly, necessitating immediate intervention. Remote care models must establish clear transfer protocols and pre-established relationships with local emergency departments. Care coordinators in this study were tasked with identifying a nearby hospital capable of managing symptomatic ARIA if inpatient care was required, ensuring a safety net was in place before the first drop of medication was infused.
"Families affected by Alzheimer's shouldn't have to choose between treatment and a long drive or a months-long wait for a specialist," said Sandra Abrevaya, Chief Executive Officer of Synapticure. "These data are an early sign that a virtual-first model can expand access to new therapies."
The Reimbursement Hurdle and Industry Impact
Beyond clinical feasibility, the viability of a decentralized specialty care network depends heavily on navigating a labyrinthine reimbursement and regulatory landscape. Delivering high-cost infused biologics across state lines introduces significant administrative friction.
Physicians must generally be licensed in the state where the patient is located during the telehealth visit. While the Interstate Medical Licensure Compact (IMLC) has streamlined this process, managing multi-state compliance remains a substantial operational cost for nationwide virtual practices.
Furthermore, while Medicare has permanently expanded many telehealth flexibilities post-pandemic and established National Coverage Determinations (NCDs) for amyloid-targeting monoclonal antibodies, the specific billing rules for remote specialist oversight of infusion drugs remain incredibly complex. Commercial payers universally require rigorous prior authorization for high-cost biologics, and policies regarding remote monitoring codes for ARIA surveillance—such as virtual check-ins and remote image interpretation—are still evolving across different health plans.
Despite these hurdles, the industry implications of the CTAD presentation are profound. As the pipeline for complex, monitoring-heavy specialty pharmaceuticals grows—not just in neurodegeneration, but across oncology and autoimmune diseases—the need for scalable delivery models will only intensify.
If virtual specialty practices can consistently prove that remote oversight matched with local infrastructure equals safe, effective care, they will not only dismantle the specialist deserts plaguing Alzheimer's patients but also set a new template for the future of decentralized medicine. The initial data suggests this future may be closer than previously imagined, provided the healthcare system can adapt its regulatory and reimbursement frameworks to support it.
Topics & Related
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →